Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges in Implementing Futility Schemes, with Reference to Aducanumab.

Paul Gallo1, Satrajit Roychoudhury2

  • 1Independent Consultant, East Hanover, NJ, USA.

Therapeutic Innovation & Regulatory Science
|February 3, 2023
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bayesian randomized basket trial design: a case study from the ultra-rare invasive mold infections.

Biometrics·2026
Same author

Single-Center Experience with Sonic Estimation of Elasticity via Resonance (SEER)-Guided Hemostasis in Adult Cardiac Surgical Patients.

Journal of cardiothoracic and vascular anesthesia·2025
Same author

Evaluating longitudinal treatment effects for Duchenne muscular dystrophy using dynamically enriched Bayesian small sample, sequential, multiple assignment randomized trial (snSMART).

Biometrics·2025
Same author

Study duration prediction for clinical trials with time-to-event endpoints accounting for heterogeneous population.

Journal of biopharmaceutical statistics·2025
Same author

Handling missing values in patient-reported outcome data in the presence of intercurrent events.

BMC medical research methodology·2025
Same author

Propensity score weighted multi-source exchangeability models for incorporating external control data in randomized clinical trials.

Statistics in medicine·2024
Same journal

Understanding the Added Value of Action Limits for QTL Monitoring.

Therapeutic innovation & regulatory science·2026
Same journal

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Therapeutic innovation & regulatory science·2026
Same journal

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context.

Therapeutic innovation & regulatory science·2026
Same journal

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials.

Therapeutic innovation & regulatory science·2026
Same journal

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China.

Therapeutic innovation & regulatory science·2026
Same journal

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA.

Therapeutic innovation & regulatory science·2026
See all related articles

Clinical trials can be stopped early for futility, but interim data can be misleading. Careful planning of futility stopping rules is critical to avoid premature termination of potentially successful studies.

Area of Science:

  • Clinical trial design
  • Biostatistics
  • Neurodegenerative disease research

Background:

  • Early termination of clinical trials based on interim analyses, termed "futility" stopping, is common practice.
  • Premature trial cessation due to misleading interim data carries severe consequences.
  • The aducanumab Phase III program halt and subsequent regulatory submission highlight the complexities of futility assessments.

Purpose of the Study:

  • To examine the critical principles for planning and implementing futility stopping guidelines in clinical trials.
  • To illustrate the potential pitfalls of interim analyses using the aducanumab Alzheimer's disease trial as a case study.

Main Methods:

  • Review of clinical trial design principles related to interim analyses and futility stopping.
Keywords:
Alzheimer’s diseaseConditional powerFutility analysisInterim analysis

Related Experiment Videos

  • Case study analysis of the aducanumab Phase III program's termination and subsequent data re-evaluation.

    • Main Results:

    • Interim data used for futility judgments can be misleading, potentially leading to incorrect trial closures.
    • Re-examination of data after initial futility assessment in the aducanumab trials led to a regulatory submission, demonstrating the impact of data interpretation.

    Conclusions:

    • Futility stopping rules must be meticulously planned and cautiously implemented to mitigate risks associated with interim data.
    • The aducanumab case underscores the need for robust methodologies and careful consideration when making decisions about early trial termination.